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We greatly appreciate, and are impressed by, the article 
written by Halina Bartosik-Psujek and Marek Psujek who 
reviewed the state of current knowledge regarding vita-
min D [25(0H)D] as an immune modulator in multiple 
sclerosis (MS), especially regarding 25(0H)D’s effect on 
immune cells subsets in relation to experimental and 
clinical studies [1]. 
25(0H)D maintains calcium-phosphate homeostasis 
and modulates an immune response. 25(0H)D inhibits the 
maturation of antigen-presenting dendritic cells (DCs), the 
proliferation  of T and B cells, the Th1 and Th17 response, 
the expression of MHC class II, CD40, CD80, CD86, and 
the production of IgG, IgM and pro-inflammatory IL-1, 
IL-6, IL-12, TNFα. 25(0H)D increases the differentiation of 
T regulatory cells (Treg), the proliferation of macrophages, 
and the Th2 response and production of anti-inflammatory 
IL-10 [1]. The main route for obtaining 25(0H)D is sunlight 
exposure, because dietary intake accounts only for 30% of the 
total amount of 25(0H)D [2].
MS is a chronic inflammatory and neurodegenerative 
disorder of the central nervous system (CNS) leading to 
demyelination, axonal loss and damage of oligodendrocytes. 
25(0H)D is one of the environmental factors which seem to 
play an important role in the aetiopathogenesis of MS and 
influences the course of the disease. 
However, the impact of 25(0H)D concentration on MS 
development and the clinical and radiological activity of the 
disease is still inconclusive [1]. In many studies, higher con-
centrations of 25(0H)D have been associated with a reduced 
risk for MS development and with reduced clinical activity of 
MS, in terms of a low rate of disease relapse, slow disability 
progression, and low disease activity measured on brain MRI 
[3, 4]. 25(0H)D supplementation alone, or as an add-on to 
a disease-modifying therapy (DMT) in patients with MS, has 
been shown to significantly reduce new T2-hyperintense and 
gadolinium-enhanced lesions on brain MRI [5], although 
other studies have found no influence on disease activity on 
brain MRI [6, 7]. 
Referring to the article, we would like to present the re-
sults of a study comparing the concentrations of 25(0H)D in 
serum, assessed using an ELISA Kit (ImmunDiagnostik AG, 
Bensheim, Austria) with a microplate reader μQuant (Biotek 
Instruments Inc.,Winooski, Vermont, USA) in patients with 
relapsing-remitting multiple sclerosis (RRMS) and in healthy 
subjects from a control group (CG) (Tab. 1). None of the 
individuals was taking a 25(0H)D supplement, and none had 
symptoms of acute inflammation (their C reactive protein con-
centration was within the normal range i.e. < 10 mg/L) (Tab. 1). 
The study protocol was approved by the Medical University of 
Bialystok Ethics Committee for Research on Humans and Ani-
mals (R-I-002/171/2018). The MS patients (mean time from 
diagnosis 8 ± 0.5 years) were treated with interferon-β 1b in 
the Department of Neurology, Medical University of Bialystok. 
All patients with MS within the last 12 months had had a brain 
MRI and none had been treated with corticosteroids within the 
past six months.  In patients with MS we assessed  correlations 
between 25(0H)D concentrations and the season of the year 
in which they were born, the number of disease relapses, and 
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Table 1. Clinical characteristics of patients with relapsing-remitting multiple sclerosis (RRMS) and the control group (CG)






RRMS 57 (40) 43.7 ± 9.5 1.9 ± 1.2 1.0 ± 1.5
CG 19 (17) 41.7 ± 2.5 — 0.9 ± 0.5





















the new T2-hyperintense and gadolinium-enhanced lesions 
on brain MRI and the EDSS score.
We found no statistically significant differences between 
the concentrations of 25(0H)D in the serum of patients with 
RRMS (18.90 ± 6.96 ng/mL) and the control group (19.47 ± 
7.78 ng/mL) (p < 0,897) (Fig. 1). 25(0H)D concentrations 
were below laboratory standards (30–40 ng/mL) in 52 patients 
(91.2%) with RRMS and in 18 subjects in the control group 
(94.7%). In patients with RRMS we observed a statistically 
significant relationship between concentrations of 25(0H)D 
and the number of disease relapses (p < 0.032). There was no 
statistically significant relationship between concentrations 
of 25(0H)D and the number of new T2-hyperintense lesions 
and the new gadolinium-enhanced lesions on brain MRI, the 
season of the year of birth, or the EDSS score.
In relation to the article written by Halina Bartosik-Psujek 
and Marek Psujek, our results cast doubt as to whether low 
serum 25(0H)D concentration is a reliable risk factor for 
developing MS. This is because almost all patients suffering 
from MS, as well as healthy controls, had low serum levels, 
which may result from insufficient sun exposure, the use of sun 
block, limited time spent in outdoor activity, staying indoors, 
and / or low 25(0H)D dietary intake [8]. 
Therefore, 25(0H)D should be supplemented in the whole 
population, especially in MS patients, according to the proven 
relationship between its concentration and the number of 
disease relapses.
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Figure 1. 25(0H)D concentrations in serum of patients with relaps-
ing-remitting multiple sclerosis (RRMS) and in the control group 
(CG); Kruskal-Wallis test with post hoc Dwass-Steele-Critchlow-
Fligner test (p < 0.897)
